Daratumumab Therapy for Smoldering Myeloma Extends Progression-Free SurvivalMultiple Myeloma, Web Exclusives
Atlanta, GA—Single-agent daratumumab (Darzalex) shows significant activity in smoldering multiple myeloma (SMM). The 12-month progression-free survival (PFS) rate with a long dosing schedule of daratumumab was 95%, and the median PFS was not yet reached in any of the 3 dosing schedules studied, announced Craig C. Hofmeister, MD, MPH, Associate Professor, Division of Hematology, the Ohio State University, Columbus, at ASH 2017.
These results from the phase 2 clinical trial CENTAURUS support a long dosing schedule of 16 mg/kg intravenously in 8-week cycles from the phase 3 study, AQUILA.
Current guidelines recommend only monitoring patients with SMM every 3 to 6 months for progression to active multiple myeloma before initiating treatment. However, a previous phase 3 study (QuiRedex) enhanced survival with lenalidomide (Revlimid) and pulsed dexamethasone in patients with high-risk SMM. “Hence, it’s appealing to try to treat patients with intermediate- and high-risk SMM to try to get some clinical benefit,” said Dr Hofmeister.
Daratumumab acts through multiple mechanisms, he said. It has direct on-tumor activity that may contribute to rapid response and its immunomodulatory actions, including modulation of the tumor microenvironment and depletion of CD38-positive immunosuppressive cells, may promote deep and durable responses.
CENTAURUS randomized 123 patients with a diagnosis of SMM of less than 5 years, bone marrow plasma cells ≥10% to <60%, and at least 1 high-risk criterion. Patients with ≥1 multiple myeloma–defining events by SLiM-CRAB criteria were excluded. The patients were randomized to 1 of 3 dosing schedules:
- A long regimen with the weekly administration of daratumumab in cycle 1, every other week in cycles 2 and 3, every 4 weeks in cycles 4 through 7, and every 8 weeks up to cycle 20
- An intermediate schedule in which daratumumab was given weekly in cycle 1, and every 8 weeks up to cycle 20
- A short, intense dosing schedule in which daratumumab was given weekly for 1 cycle.
Serologic monitoring using International Myeloma Working Group (IMWG) criteria and magnetic resonance imaging was performed every 6 months for the first 3 years. The patients were followed until progressive disease or until the end of the study.
Approximately 80% of patients in each arm had ≥2 high-risk factors at screening. The median time from the diagnosis of SMM to randomization was 6.47, 5.52, and 7.43 months in the long, intermediate, and short schedule arms, respectively.
With a median follow-up of 15.8 months, 5 (12%) patients in the long arm discontinued treatment, with 2 (5%) resulting from adverse events and 2 (5%) from progressive disease. The discontinuation rates in the intermediate- and short-schedule arms were 10% and 5%, respectively.
The 12-month PFS rates were 95% with the long schedule, 88% with an intermediate dosing schedule, and 81% with the short schedule of daratumumab. A median PFS of ≥24 months was a coprimary end point and was achieved in each arm.
More than half (54%) of the patients in the long-schedule arm and 49% in the intermediate-schedule arm had a partial response or better compared with 38% in the short arm. The other coprimary end point, a complete response of >15%, was not met. The complete response rates were 2% in the long-schedule arm, 5% in the intermediate-schedule arm, and 0% in the short-schedule arm.
A modified PFS based on biochemical progression was added to the analysis. Biochemical progression was defined as a measurable disease increase from nadir by ≥25% in 2 subsequent assessments per the IMWG criteria. The 12-month modified PFS rates were 93%, 75%, and 56% in the long-, intermediate-, and short-schedule arms, respectively. “From a clinical efficacy perspective, this supports the long dosing schedule for a subsequent phase 3 trial,” said Dr Hofmeister.
The safety profile was consistent with other single-agent daratumumab trials. The rate of hematologic treatment-emergent adverse events was <15% across all arms and the rates of grade 3 and 4 infections were ≤5% across all arms.
Overexpression of the epidermal growth factor receptor (EGFR) is correlated with poor prognosis in many human cancers.1 EGFR is a member of the ErbB family of receptor tyrosine kinases (TKs). EGFR activation occurs in response to ligand stimulation and/or genetic alterations of the EGFR gene, such as somatic mutations, amplifications, [ Read More ]
Biomarker-Guided Targeted and Checkpoint Inhibitor Therapy in Melanoma: Best Practices from the City of Hope Comprehensive Cancer Center
The target audience for this series includes physicians (medical and surgical oncologists, interventional radiologists), oncology nurse navigators, oncology nurses, pathologists, oncology pharmacists, and other stakeholders involved in delivering personalized care to cancer patients.